4'-methyl-biphenyl-3-carboxylic acid amide | 147404-70-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-methyl-biphenyl-3-carboxylic acid amide
• 英文别名: 4'-Methylbiphenyl-3-carboxamide；3-(4-Methylphenyl)benzamide
• CAS: 147404-70-4
• 化学式: C₁₄H₁₃NO
• 分子量: 211.263
• InChiKey: WLVQGXAYJIUDOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  间氯苯甲酰胺 、 4-甲苯硼酸 在 [Na₂PdCl₄] 、 (9-ethyl-2-(SO₃H)-fluorenyl)dicyclohexylphosphonium HSO₄ potassium carbonate 作用下， 以 水 为溶剂， 反应 2.5h， 生成 4'-methyl-biphenyl-3-carboxylic acid amide
  参考文献：
  名称：

  9-芴基膦在有机溶剂和水中用于Pd催化的Sonogashira，suzuki和Buchwald-Hartwig偶联反应。

  摘要：

  芴的锂化/烷基化导致各种9-烷基芴（烷基= Me，Et，iPr，-Pr，-C18H25）> 95％的收率，对此进行锂化和与R2PC1的反应（R = Cy，iPr，tBu ）生成9-烷基，9-PR2-芴，它们构成了富电子且庞大的膦配体。在有机溶剂中的芳基氯化物和芳基溴化物的Sonogashira，Suzuki和Buchwald-Hartwig反应中测试了原位形成的钯-膦配合物（[Na2PdCl4] 、,盐，碱，底物）。在1-mol％的Pd催化剂下，在100-120摄氏度下，芳基氯化物的Sonogashira偶联可导致> 90％的收率。芳基氯的Suzuki偶联通常需要在100摄氏度的二恶烷中加入0.05摩尔％的Pd催化剂，以定量形成产物。为了在水中进行“绿色”交叉偶联反应，使9-乙基芴基二环己基膦在硫酸中反应，生成相应的2-磺化phospho盐。通过使用这种水溶性催化剂进行的活化芳基氯的Suzuki偶联仅需要0

  DOI：

  10.1002/chem.200601142

文献信息

• New cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions
  申请人：Evonik Degussa GmbH

  公开号：EP1894938A1

  公开（公告）日：2008-03-05

  The invention is directed to a phosphine compound represented by general formula (1) wherein R' and R" independently are selected from alkyl, cycloalkyl and 2-furyl radicals, or R' and R" are joined together to form with the phosphorous atom a carbon-phosphorous monocycle comprising at least 3 carbon atoms or a carbon-phosphorous bicycle; the alkyl radicals, cycloalkyl radicals, and carbon-phosphorous monocycle being unsubstituted or substituted by at least one radical selected from the group of alkyl, cycloalkyl, aryl, alkoxy, and aryloxy radicals; Cps is a partially substituted or completely substituted cyclopentadien-1-yl group, including substitutions resulting in a fused ring system, and wherein a substitution at the 1-position of the cyclopentadien-1-yl group is mandatory when the cyclopentadien-1-yl group is not part of a fused ring system or is part of an indenyl group. Also claimed is the use of these phosphines as ligands in catalytic reactions and the preparation of these phosphines.

  该发明涉及一种由通式（1）表示的膦化合物 其中 R'和R"独立地选自烷基、环烷基和2-呋喃基，或者R'和R"结合在一起与磷原子形成至少含有3个碳原子的碳-磷单环或碳-磷双环；所述烷基基团、环烷基基团和碳-磷单环未取代或取代，所述取代包括来自烷基、环烷基、芳基、烷氧基和芳氧基基团中至少一个基团的选择； Cps是部分取代或完全取代的环戊二烯-1-基团，包括导致融合环系统的取代，当环戊二烯-1-基团不是融合环系统的一部分或是茚基团的一部分时，环戊二烯-1-基团的1-位取代是强制的。还声明了这些膦化合物作为催化反应中的配体以及这些膦化合物的制备的用途。
• [EN] HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1<br/>[FR] AMIDES HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DE LA TRPA1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010141805A1

  公开（公告）日：2010-12-09

  Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

  描述了某些杂环酰胺化合物。这些化合物可用于制备药物组合物，以及用于治疗由TRPA1活性介导的疾病状态、紊乱和条件，如疼痛、关节炎、瘙痒、咳嗽、哮喘或炎症性肠病的方法。
• CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS
  申请人：Plenio Herbert

  公开号：US20090253907A1

  公开（公告）日：2009-10-08

  A phosphine compound represented by general formula (1) wherein R′ and R″ independently are selected from alkyl, cycloalkyl and 2-furyl radicals, or R′ and R″ are joined together to form with the phosphorous atom a carbon-phosphorous monocycle including at least 3 carbon atoms or a carbon-phosphorous bicycle; the alkyl radicals, cycloalkyl radicals, and carbon-phosphorous monocycle being unsubstituted or substituted by at least one radical selected from the group of alkyl, cycloalkyl, aryl, alkoxy, and aryloxy radicals; Cp s is a partially substituted or completely substituted cyclopentadien-1-yl group, including substitutions resulting in a fused ring system, and wherein a substitution at the 1-position of the cyclopentadien-1-yl group is mandatory when the cyclopentadien-1-yl group is not part of a fused ring system or is part of an indenyl group. These phosphines can be used as ligands in catalytic reactions.

  一种磷化合物，其通式表示为（1），其中R'和R''独立地选择烷基，环烷基和2-呋喃基基团，或者R'和R''与磷原子结合形成至少包括3个碳原子的碳-磷单环或碳-磷双环；烷基基团，环烷基基团和碳-磷单环未经取代或被至少一种从烷基，环烷基，芳基，烷氧基和芳氧基基团组成的基团取代；Cps是部分取代或完全取代的环戊二烯-1-基基团，包括导致融合环系统的取代，当环戊二烯-1-基基团不是融合环系统的一部分或是一个茚基基团的一部分时，必须在环戊二烯-1-基基团的1位进行取代。这些磷化物可以用作催化反应中的配体。
• Biphenyl Derivatives and Their Use in Treating Hepatitis C
  申请人：Wheelhouse Christopher James

  公开号：US20080255105A1

  公开（公告）日：2008-10-16

  A compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof wherein: R 1 is a C 1 -C 6 alkyl group or a moiety -A 1 , -L 1 -A 1 , -A 1 -A 1 ′, -L 1 -A 1 -A 1 ′, -A 1 -L 1 -A 1 ′, -A 1 -Y 1 -A 1 ′, -A 1 -Het 1 -A 1 ′, -L 1 -A 1 -Y 1 -A 1 ′, -L 1 -A 1 -Het 1 -A 1 ′, -L 1 -Het 1 -A 1 , -L 1 -Y 1 -A 1 , -L 1 -Y 1 -Het 1 -A 1 , -L 1 -Het 1 -Y 1 -A 1 , -L 1 -Y 1 -Het 1 -L 1 ′, -A 1 -Y 1 -Het 1 -A 1 ′, -A 1 -Het 1 -Y 1 -A 1 ′, -A 1 -Het 1 -L 1 -A 1 ′, -A 1 -L 1 -Het 1 -A 1 ′ or -L 1 -Het 1 -L 1 ′; -A and B are the same or different and each represent a direct bond or a —CO—NR′—, —NR′—CO—, —NR′—CO 2 —, —CO—, —NR′—CO—NR″—, —NR′—S(O) 2 —, —S(O) 2 —NR′—, —SO 2 —, —NR′—, —NR′—CO—CO—, —CO—O—, —O—CO—, —(C 1 -C 2 alkylene)-NR′— or —(C 1 -C 2 hydroxyalkylene)-NR′-moiety, wherein R′ and R″ are the same or different and each represent hydrogen or C 1 -C 4 alkyl; —R 2 and R 3 are the same or different and each represent C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy or halogen; n and m are the same or different and each represent 0 or 1; R 4 is a C 1 -C 6 alkyl group or a moiety -A 4 , -L 4 -A 4 , -A 4 -A 4 ′, -L 4 -A 4 -A 4 ′, -A 4 -L 4 -A 4 ′, -A 4 -Y 4 -A 4 ′, -A 4 -Het 4 -A 4 ′, -L 4 -A 4 -Y 4 -A 4 ′, -L 4 -A 4 -Het 4 -A 4 ′, -L 4 -Het 4 -A 4 , -L 4 -Y 4 -A 4 , -L 4 -Y 4 -Het 4 -A 4 , -L 4 -Het 4 -Y 4 -A 4 , -L 4 -Y 4 -Het 4 -L 4 ′, -A 4 -Y 4 -Het 4 -A 4 ′, -A 4 -Het 4 -Y 4 -A 4 ′, -A 4 -Het 4 -L 4 -A 4 ′, -A 4 -L 4 -Het 4 -A 4 ′ or -L 4 -Het 4 -L 4 ′, each A 1 , A 4 , A 1 ′ and A 4 ′ are the same or different and represent a phenyl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocyclyl or C 3 -C 8 carbocyclyl moiety; each L 1 and L 4 is the same or different and represents a C 1 -C 4 alkylene or a C 1 -C 4 hydroxyalkylene group; each Y 1 and Y 4 is the same or different and represents —CO—, —SO— or —S(O) 2 —; each L 1 ′ and L 4 ′ is the same or different and represents hydrogen or a C 1 -C 4 alkyl group; and each Het 1 and Het 4 is the same or different and represents —O—, —S— or —NR′—, wherein R′ is hydrogen or a C 1 -C 4 alkyl group, the phenyl, heteroaryl, heterocyclyl and carbocyclyl moieties in R 1 and R 4 being optionally fused to a phenyl, 5- to 10-membered heteroaryl or 5- to 10-membered heterocyclyl ring; and the phenyl, heteroaryl, heterocyclyl and carbocyclyl moieties in R 1 and R 4 being unsubstituted or substituted by (a) a single unsubstituted substituent selected from —(C 1 -C 4 alkyl)-X 1 , —CO 2 R′, —SO 2 NR′R″, —S(O) 2 —R′, —CONR′R″, —NR′—CO—R′″, —NR′—S(O) 2 —R′″, —CO—NR′—(C 1 -C 4 alkyl)-NR′R″ and —CO—O—(C 1 -C 4 alkyl)-NR′R″ and/or (b) 1, 2 or 3 unsubstituted substituents selected from —(C 1 -C 4 alkyl)-X 2 , halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 hydroxyalkyl, hydroxy, cyano, nitro and —NR′R″, wherein X 1 is —CO 2 R′, —SO 2 —R′, —NR′—CO 2 —R″, —NR′—S(O) 2 —R′″, —CONR′R″ or —SO 2 —NR′R″, each X 2 is the same or different and is cyano, nitro or —NR′R″, each R′ and R″ is the same or different and represents hydrogen or C 1 -C 4 alkyl and each R′″ is the same or different and represents C 1 -C 4 alkyl.

  化合物是公式（I）的二苯基衍生物，或其药学上可接受的盐，其中：R1是C1-C6烷基或基-A1，-L1-A1，-A1-A1'，-L1-A1-A1'，-A1-L1-A1'，-A1-Y1-A1'，-A1-Het1-A1'，-L1-A1-Y1-A1'，-L1-A1-Het1-A1'，-L1-Het1-A1，-L1-Y1-A1，-L1-Y1-Het1-A1，-L1-Het1-Y1-A1，-L1-Y1-Het1-L1'，-A1-Y1-Het1-A1'，-A1-Het1-Y1-A1'，-A1-Het1-L1-A1'，-A1-L1-Het1-A1'或-L1-Het1-L1'的基团；A和B相同或不同，每个代表直接键或-CO-NR'，-NR'-CO，-NR'-CO2，-CO，-NR'-CO-NR"，-NR'-S（O）2，-S（O）2-NR'，-SO2，-NR'，-NR'-CO-CO-，-CO-O-，-O-CO-，-（C1-C2烷基）-NR'或-（C1-C2羟基烷基）-NR'基团，其中R'和R"相同或不同，每个代表氢或C1-C4烷基；-R2和R3相同或不同，每个代表C1-C4烷基，C1-C4烷氧基，C1-C4卤代烷基，C1-C4卤代烷氧基或卤素；n和m相同或不同，每个代表0或1；R4是C1-C6烷基或基-A4，-L4-A4，-A4-A4'，-L4-A4-A4'，-A4-L4-A4'，-A4-Y4-A4'，-A4-Het4-A4'，-L4-A4-Y4-A4'，-L4-A4-Het4-A4'，-L4-Het4-A4，-L4-Y4-A4，-L4-Y4-Het4-A4，-L4-Het4-Y4-A4，-L4-Y4-Het4-L4'，-A4-Y4-Het4-A4'，-A4-Het4-Y4-A4'，-A4-Het4-L4-A4'，-A4-L4-Het4-A4'或-L4-Het4-L4'，每个A1，A4，A1'和A4'相同或不同，代表苯基，5-至10-成员杂芳基，5-至10-成员杂环基或C3-C8碳环基基团；每个L1和L4相同或不同，代表C1-C4烷基或C1-C4羟基烷基基团；每个Y1和Y4相同或不同，代表-CO-，-SO-或-S（O）2-；每个L1'和L4'相同或不同，代表氢或C1-C4烷基基团；每个Het1和Het4相同或不同，代表-O-，-S-或-NR'-，其中R'是氢或C1-C4烷基，R1和R4中的苯基，杂芳基，杂环基和碳环基基团可以选择地与苯基，5-至10-成员杂芳基或5-至10-成员杂环基环融合；R1和R4中的苯基，杂芳基，杂环基和碳环基基团可以未经取代或经过（a）单个未取代的取代基的取代，所选的取代基为-（C1-C4烷基）-X1，-CO2R'，-SO2NR'R"，-S（O）2-R'，-CONR'R"，-NR'-CO-R'"，-NR'-S（O）2-R'"，-CO-NR'（C1-C4烷基）-NR'R"和-CO-O-（C1-C4烷基）-NR'R"和/或（b）1,2或3个未取代的取代基，所选的取代基为-（C1-C4烷基）-X2，卤素，C1-C4烷基，C1-C4烷氧基，C1-C4卤代烷基，C1-C4卤代烷氧基，C1-C4羟基烷基，羟基，氰基，硝基和-NR'R"，其中X1为-CO2R'，-SO2-R'，-NR'-CO2-R"，-NR'-S（O）2-R'"，-CONR'R"或-SO2-NR'R"，每个X2相同或不同，为氰基，硝基或-NR'R"，每个R'和R"相同或不同，代表氢或C1-C4烷基，每个R'"相同或不同，代表C1-C4烷基。
• New Cyclopentadienyl, Indenyl or Fluorenyl Substituted Phosphine Compounds and their Use in Catalytic Reactions
  申请人：PLENIO Herbert

  公开号：US20120245348A1

  公开（公告）日：2012-09-27

  Disclosed herein are phosphine compounds represented by the general formula (4): and corresponding phosphonium salts represented by the general formula (4a): Also disclosed are processes for the preparation of these phosphines and phosphonium salts as well as their use as ligands in catalytic reactions.

  本文披露了由一般式（4）表示的膦化合物和由一般式（4a）表示的相应膦鎵鹽，同时还披露了制备这些膦化合物和膦鎵鹽的过程，以及它们作为催化反应中的配体的用途。